Get the Weekly Intelligence Brief — top committee picks every Sunday.
NVST · NYSE · STOCK

Envista Holdings (NVST) Stock Analysis

Healthcare Updated October 16, 2026
$22.91
52W $18.77 – $30.42
62/100
$3.77B
39.8
0.89
AI Committee Verdict
Buy
62/100
Conviction: Moderate · 60% agreement · 5 analysts
+11.8%
-1.7%
7.14:1
Moderate

Is NVST Bullish or Bearish?

Bullish. Innellis AI committee rates Envista Holdings (NVST) Buy with a composite score of 62/100 , based on 5 analysts with 60% agreement. Last updated October 16, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.42 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.58 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 83.6% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2739.42). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.1x is a discount to asset value — Value
  • EPS growing 83.6% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • P/E of 39.6 is moderate-to-rich — Value
  • ROE of only 3.1% -- cheap may mean cheap for a reason — Value
  • Price structure making lower highs and lower lows — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 16, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 22%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.1x is a discount to asset value
− P/E of 39.6 is moderate-to-rich
Growth Analyst bullish
79 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 83.6% YoY
Technical Analyst neutral
52 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2739.42)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 62.3 to 61.6.

Analyst-level changes:
  • News Analyst: stance bullish->neutral; score 61->58 (-4).
  • Portfolio Manager: +1 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-15 to 2026-10-16 (1 day apart).

Technical Analysis

RSI (14)
55.4
Neutral
MACD Histogram
0.106
Bullish Momentum
Trend Direction
Downtrend
Weekly: Sideways
Market Structure
Mixed
Support
$22.52
Resistance
$25.62
Bollinger %B
0.58
Inside Bands
Price vs Moving Averages
EMA 9
$23.10 Below
EMA 21
$23.65 Below
EMA 50
$24.76 Below
EMA 200
$24.85 Below

Fundamental Analysis

Valuation
67
Growth
95
Profitability
30
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 39.8×
P/B Ratio 1.24×
PEG Ratio 0.44
Dividend Yield 0.00%
52W High $30.42
52W Low $18.77
Quality & Growth
ROE 151.3%
ROA 82.8%
Gross Margin 5549.8%
Operating Margin 992.1%
Revenue Growth YoY —
Debt / Equity 0.52
AI Fundamental Assessment
P/E ratio of 39.8 (rich relative to a 15-40x range); Price-to-book of 1.2x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 1.5%; Return on assets of 0.8%; Net margin of 3.3%; Gross margin of 55.5%; Current ratio of 2.43 (healthy short-term liquidity); Debt-to-equity of 0.52; Free cash flow per share is positive (1.43); Most recent quarter beat estimates by 19.9%; 5 consecutive earnings beats; EPS growth accelerating (-5.3% -> +13.9% QoQ); Average YoY EPS growth of 57.7%; Analyst estimates rising over recent quarters
Get the Full NVST Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime